A new article published in the International Journal of Molecular Sciences described atopic dermatitis (AD),as a predominant and deteriorating chronic inflammation of the skin—categorized by robust burning and eczematous lacerations in diverse portions of the body. The authors stated that AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary and immunological factors, along with the skin barrier dysfunction. Measures used to prevent the disease are everyday usage of creams to support restoration of the epidermal barrier. Classical treatments include the use of topical corticosteroids as a first-line therapy, as well as calcineurin inhibitors, antihistamines, antibiotics, phototherapy and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin’s anatomic barrier, which limits the deeper penetration of drugs. This article reported that groundbreaking drug delivery systems based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells and limiting secondary effects of drugs employed in the treatment of AD. Yet, additional studies are required to recognize the toxicological characteristics and long-term safety of NPs.